Versions Compared


  • This line was added.
  • This line was removed.
  • Formatting was changed.


Download the PDF: Notarangelo_Luigi_oral_history (108 kB)

Read a paper: See the extensive list at the end of the interview.

Dr. Luigi Notarangelo Oral history


LN: Thank you, likewise. Thank you very much. It's been a pleasure.

Read a paper:
Autoantibodies against type I IFNs in patients with life-threatening COVID-19, Science, 2020 Oct 23; 370(6515) :eabd4585.  doi: 10.1126/science.abd4585. Epub 2020 Sep 24.

Inborn errors of type I IFN immunity in patients with life-threatening COVID-19, Science, 2020 Oct 23; 370(6515): eabd4570.   doi: 10.1126/science.abd4570. Epub 2020 Sep 24.

Severe COVID-19 in the young and healthy: monogenic inborn errors of immunity?, Nat Rev Immunol, 2020 Aug; 20(8): 455-456.   doi: 10.1038/s41577-020-0373-7.

An immune-based biomarker signature is associated with mortality in COVID-19 patients, JCI Insight, 2021 Jan 11; 6(1): e144455.  doi: 10.1172/jci.insight.144455.

A Global Effort to Define the Human Genetics of Protective Immunity to SARS-CoV-2 Infection, Cell, 2020 Jun 11; 181(6): 1194-1199.   doi: 10.1016/j.cell.2020.05.016. Epub 2020 May 13

Life-Threatening COVID-19: Defective Interferons Unleash Excessive Inflammation, Med (N Y), 2020 Dec 18; 1(1): 14-20.  doi: 10.1016/j.medj.2020.12.001.

Flow Cytometry Identifies Risk Factors and Dynamic Changes in Patients with COVID-19, J Clin Immunol, 2020 Oct; 40(7): 970-973.  doi: 10.1007/s10875-020-00806-6. Epub 2020 Jun 27.

Reduction in the rate and improvement in the prognosis of COVID-19 in haematological patients over time, Leukemia, 2021 Feb; 35(2): 632-634.   doi: 10.1038/s41375-020-01015-1. Epub 2020 Aug 7.

Harnessing Type I IFN Immunity Against SARS-CoV-2 with Early Administration of IFN-β, J Clin Immunol, 2021 Oct; 41(7): 1425-1442.   doi: 10.1007/s10875-021-01068-6. Epub 2021 Jun 8.

SARS-CoV-2-related MIS-C: A key to the viral and genetic causes of Kawasaki disease?, J Exp Med, 2021 Jun 7; 218(6): e20210446.   doi: 10.1084/jem.20210446.

Inhibition of HECT E3 ligases as potential therapy for COVID-19, Cell Death Dis, 2021 Mar 24; 2(4) :310.   doi: 10.1038/s41419-021-03513-1.

X-linked recessive TLR7 deficiency in ~1% of men under 60 years old with life-threatening COVID-19, Sci Immunol, 2021 Aug 19; 6(62): eabl4348. doi: 10.1126/sciimmunol.abl4348.

Time-resolved systems immunology reveals a late juncture linked to fatal COVID-19, Cell, 2021 Apr 1; 184(7): 1836-1857.e22.   doi: 10.1016/j.cell.2021.02.018. Epub 2021 Feb 10.

Antibody responses to the SARS-CoV-2 vaccine in individuals with various inborn errors of immunity, J Allergy Clin Immunol, 2021 Nov; 148(5): 1192-1197.   doi: 10.1016/j.jaci.2021.08.016. Epub 2021 Sep 4.

SARS-CoV-2 Spike Protein-Directed Monoclonal Antibodies May Ameliorate COVID-19 Complications in APECED Patients, Front Immunol, 2021 Aug 24; 12: 720205.  doi: 10.3389/fimmu.2021.720205. eCollection 2021.

Autoantibodies neutralizing type I IFNs are present in ~ 4% of uninfected individuals over 70 years old and account for ~ 20% of COVID-19 deaths, Sci Immunol, 2021 Aug 19; 6(62): eabl4340.  doi: 10.1126/sciimmunol.abl4340.

Robust Antibody and T Cell Responses to SARS-CoV-2 in Patients with Antibody Deficiency, J Clin Immunol, 2021 Aug; 41(6): 1146-1153.   doi: 10.1007/s10875-021-01046-y. Epub 2021 May 13.

BTK inhibitors for severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): A systematic review, Clin Immunol, 2021 Sep; 230: 108816.   doi: 10.1016/j.clim.2021.108816. Epub 2021 Aug 2. 

Preexisting autoantibodies to type I IFNs underlie critical COVID-19 pneumonia in patients with APS-1, J Exp Med,, 2021 Jul 5; 218(7): e20210554.  doi: 10.1084/jem.20210554.

Association of rare predicted loss-of-function variants of influenza-related type I IFN genes with critical COVID-19 pneumonia, J Clin Invest, 2021 Aug 2; 131(15): e152474.   doi: 10.1172/JCI152474.

Neutralizing type-I interferon autoantibodies are associated with delayed viral clearance and intensive care unit admission in patients with COVID-19, Immunol Cell Biol, 2021 Oct; 99(9): 917-921.   doi: 10.1111/imcb.12495. Epub 2021 Aug 8.